Source: GlobeNewswire Inc.
Chemours faces a securities class action lawsuit for failing to disclose material information about refrigerant aftermarket demand during February-August 2026. The company cut full-year EBITDA guidance and admitted to channel oversupply, resulting in an 18.63% stock price decline on August 5, 2026. Investors have until December 7, 2026 to file lead plaintiff applications.
Source: GlobeNewswire Inc.
A class action lawsuit has been filed against Chemours Company alleging that the company failed to disclose material information about overstated aftermarket demand for Opteon products and decreasing demand, resulting in unreliable financial guidance. Investors who purchased Chemours securities between February 20, 2026 and August 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of December 7, 2026.
Source: Zacks Investment Research
Chemours (CC) reported quarterly earnings of $0.21 per share, missing the consensus estimate of $0.26 and representing a -19.23% earnings surprise. Revenues of $1.54 billion also slightly missed expectations. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, with the Chemical - Diversified industry ranking in the bottom 18% of sectors.
Source: Zacks Investment Research
Chemours reported Q3 2026 revenue of $1.54 billion, meeting consensus estimates but delivering an EPS of $0.21 versus the expected $0.26, representing a 19.23% miss. While Titanium Technologies showed strong year-over-year growth of 11.1%, Thermal & Specialized Solutions declined 8.9%. The company received a Zacks Rank #4 (Sell) rating, underperforming the S&P 500 over the past month.
Source: GlobeNewswire Inc.
A class action lawsuit has been filed against Chemours Company alleging that the company failed to disclose material information about overstated aftermarket demand for Opteon products and decreasing demand, resulting in unreliable financial guidance. Investors who purchased Chemours securities between February 20, 2026 and August 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of December 7, 2026.
Source: GlobeNewswire Inc.
A class action lawsuit has been filed against The Chemours Company (NYSE: CC) for allegedly overstating market demand for its Opteon products and providing unreliable financial guidance. The company reduced its full-year adjusted EBITDA guidance in August 2026, causing the stock to drop 18.63%. Investors who purchased CC securities between February 20, 2026 and August 4, 2026 may be eligible to participate in the lawsuit.
Source: GlobeNewswire Inc.
The Chemours Company faces a securities class action lawsuit for failing to disclose material information between February and August 2026. The company cut its full-year adjusted EBITDA guidance significantly after revealing channel oversupply issues, causing its stock to fall 18.63% on August 5, 2026. Investors with losses exceeding $100,000 have until December 7, 2026 to file lead plaintiff applications.
Source: GlobeNewswire Inc.
Kahn Swick & Foti, LLC announces a securities class action lawsuit against The Chemours Company for allegedly failing to disclose material information about refrigerant aftermarket demand during February 20 - August 4, 2026. The company cut full-year adjusted EBITDA guidance and revealed that executives misrepresented channel inventory levels, resulting in an 18.63% stock price decline on August 5, 2026. Investors have until December 7, 2026 to file lead plaintiff applications.
Source: GlobeNewswire Inc.
A class action lawsuit has been filed against Chemours Company alleging that the company failed to disclose material information about overstated aftermarket demand for Opteon products and decreasing demand, resulting in unreliable financial guidance. Investors who purchased Chemours securities between February 20, 2026 and August 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of December 7, 2026.
Source: GlobeNewswire Inc.
A securities fraud class action lawsuit has been filed against The Chemours Company for allegedly making materially false statements about financial guidance during February-August 2026. The company overstated aftermarket demand for its Opteon refrigeration products, leading to a significant stock price drop of 18.63% on August 5, 2026, after the company reduced its full-year EBITDA guidance and reported a 4% volume decline.
Source: GlobeNewswire Inc.
A class action lawsuit has been filed against Chemours Company alleging that the company failed to disclose material information about overstated aftermarket demand for Opteon products and decreasing demand, resulting in unreliable financial guidance for 2026. Investors who purchased Chemours securities between February 20, 2026 and August 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of December 7, 2026.
Source: GlobeNewswire Inc.
The Chemours Company faces a securities class action lawsuit for failing to disclose material information during February-August 2026. The company cut its full-year adjusted EBITDA guidance significantly after revealing channel oversupply issues, causing its stock to plunge 18.63% on August 5, 2026. Investors with losses exceeding $100,000 have until December 7, 2026 to file lead plaintiff applications.
Source: GlobeNewswire Inc.
A securities fraud class action lawsuit has been filed against The Chemours Company (NYSE: CC) for allegedly making materially false statements about the reliability of its financial guidance. The lawsuit covers investors who purchased CC securities between February 20, 2026 and August 4, 2026. Chemours stock fell 18.63% on August 5, 2026, after the company reduced its full-year adjusted EBITDA guidance and attributed the decline to a 4% decrease in volumes, primarily from lower Opteon refrigerant aftermarket sales. The deadline to seek lead plaintiff status is December 7, 2026.
Source: GlobeNewswire Inc.
A class action lawsuit has been filed against Chemours Company alleging that the company failed to disclose material information about overstated aftermarket demand for Opteon products and decreasing demand, resulting in unreliable financial guidance for 2026. Investors who purchased Chemours securities between February 20, 2026 and August 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of December 7, 2026.
Source: GlobeNewswire Inc.
A securities fraud class action has been filed against The Chemours Company (NYSE: CC) for allegedly overstating market demand for its Opteon products during the Class Period (February 20 - August 4, 2026). The company reduced its full-year EBITDA guidance and disclosed an oversupplied channel, causing the stock to drop 18.63% on August 5, 2026. The lead plaintiff deadline is December 7, 2026.